- New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)
asserted
findings → show → disorder
The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savings
-
asserted
UZEDY → show → savings
The breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how therapies perform in patients’ everyday lives to assist in improving routine care and reducing the burden of severe mental illness
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) —
asserted
therapies → present → illness
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension.
asserted
Pharmaceuticals → announce → UZEDY
The results demonstrate how UZEDY helps patients with schizophrenia remain on treatment longer while reducing emergency care and healthcare costs compared with other treatment options.
asserted
patients → demonstrate → options
The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
asserted
findings → present → Orleans
“We cannot accept psychiatric emergencies and hospitalizations as an inevitable part of living with schizophrenia and bipolar I disorder,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva.
asserted
Hughes → accept → Teva
“These findings show that when we provide a treatment option like UZEDY that helps patients stay on track, we can meaningfully cut emergency room visits and help people maintain stability in their everyday lives.
asserted
people → show → lives
Delivering measurable impact for patients and healthcare systems is what drives everything we do at Teva.”
asserted
we → deliver → Teva
The two schizophrenia abstracts featured at Psych Congress highlight significant clinical and economic advantages in real-world settings:
- Lower Emergency Care and Costs vs. Paliperidone Palmitate Once-Monthly (PP1m): In a matched cohort of 1,166 patients (583 per group), fewer patients receiving once-monthly UZEDY had an emergency department (ED) visit compared to PP1m (22.0% vs. 27.8%).
asserted
patients → feature → %
Overall, UZEDY patients had a 40% lower all-cause ED visit rate and a numerically lower proportion of inpatient hospitalizations (11.1% vs. 14.8%).
asserted
patients → have → %
Estimated mean monthly direct healthcare costs were significantly lower for UZEDY ($4,688.10 vs. $5,724.80), delivering an adjusted mean monthly savings of $1,036.70 per patient.
asserted
costs → deliver → patient
Matched cohorts compared once-monthly UZEDY to risperidone microspheres every-2-weeks, aripiprazole once-monthly and haloperidol decanoate once-monthly.
asserted
cohorts → match → microspheres
The greatest differences were observed against risperidone microspheres, where UZEDY patients achieved 3.6x higher odds of adherence (OR: 3.6), an 80% lower likelihood of discontinuation (OR: 0.2) and lower rates of ED visits and hospitalizations.
asserted
patients → observe → visits
UZEDY patients also had lower ED visit rates versus haloperidol decanoate once-monthly, while outcomes versus aripiprazole once-monthly were generally comparable.
asserted
outcomes → have → aripiprazole
“As clinicians, it is frustrating to watch patients with schizophrenia struggle through cycles of relapse and end up back in the emergency room,” said John M. Kane, MD, Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
asserted
Kane → watch → Northwell
“We need to think differently about how we use long-acting injectables.
asserted
we → need → injectables
This observational data shows that patients receiving UZEDY had greater treatment continuity and fewer emergency department visits, reinforcing the potential of this approach to help patients stay stable while reducing pressure on an already strained healthcare system.”
BD-I Data Highlights
Teva also presented new study findings evaluating outcomes in patients living with BD-I who switched from oral antipsychotics to UZEDY:
- Real-World Effectiveness of Switching From Oral Antipsychotics to UZEDY in BD-I:
asserted
who → show → I
A retrospective chart review of 358 matched patients (179 per group) evaluated patient outcomes after transitioning from oral antipsychotics to either UZEDY or another oral antipsychotic.
asserted
review → match → UZEDY
Patients who switched to UZEDY experienced significantly less treatment failure (47% vs. 63%) compared to those switched to another oral antipsychotic.
asserted
who → switch → antipsychotic
Patients receiving UZEDY were also more likely to stay on treatment longer without experiencing BD-I/mania-related hospitalizations, ED visits or discontinuation due to inadequate effectiveness.
asserted
Patients → receive → effectiveness
As the treatment landscape for severe mental illness continues to evolve, real-world evidence remains essential in guiding clinical decisions that optimize patient outcomes and healthcare resources.
asserted
that → continue → outcomes
These findings further validate UZEDY as an innovative, effective and economically beneficial treatment option for patients navigating the complex, daily challenges of schizophrenia and BD-I.
asserted
findings → validate → schizophrenia
About UZEDY
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
asserted
UZEDY → indicate → adults
In clinical trials, UZEDY significantly delayed time to relapse in adults with schizophrenia.1,2
asserted
UZEDY → delay → adults
UZEDY administers risperidone through copolymer technology under license from Medincell that allows for rapid absorption and sustained release after subcutaneous injection.
asserted
that → administer → injection
UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.1
asserted
UZEDY → act → intervals.1
APPROVED USE
UZEDY (risperidone) extended-release injectable suspension is a prescription medicine used in adults
- for the treatment of schizophrenia
- for the maintenance treatment of bipolar I disorder as monotherapy or as adjunctive therapy to lithium or valproate
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about UZEDY?
asserted
I → use → UZEDY
UZEDY can cause serious side effects, including an increased risk of death in elderly people who are confused, have memory loss, and have lost touch with reality (dementia-related psychosis).
asserted
who → cause → reality
UZEDY is not approved for use in patients with dementia-related psychosis.
asserted
UZEDY → approve → psychosis
Do not receive UZEDY if you are allergic to risperidone, paliperidone, or any of its components.
asserted
you → receive → components
UZEDY may cause serious side effects, including:
- Stroke in elderly people (cerebrovascular problems) that can lead to death.
- Neuroleptic Malignant Syndrome (NMS).
uncertain
that → cause → Syndrome
NMS is a rare but very serious problem that can lead to death.
asserted
that → lead → death
Seek medical attention right away if you have any of these symptoms: high fever, severe muscle stiffness, confusion, sweating, irregular heartbeat, fast heart rate, or changes in your blood pressure.
asserted
you → seek → pressure
- Uncontrolled facial or body movements (tardive dyskinesia) that may not go away, even if you stop receiving UZEDY.
uncertain
you → go → UZEDY
Tardive dyskinesia may also start after you stop receiving UZEDY.
uncertain
you → start → UZEDY
- Problems with your metabolism that may include high blood sugar (hyperglycemia), diabetes mellitus, changes in the fat levels in your blood (dyslipidemia), and weight gain.
uncertain
that → include → blood
Extremely high blood sugar can lead to coma or death.
asserted
sugar → lead → coma
If you have diabetes or are at risk for diabetes (e.g., obesity, family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with UZEDY.
asserted
you → have → UZEDY
Call your healthcare provider if you have symptoms of high blood sugar including: feeling very thirsty, hungry, sick to your stomach, weak or tired, or confused; needing to urinate more than usual; or your breath smells fruity.
asserted
breath → call → stomach
…and 37 more, not listed.
The Aporia
